Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Ann Arbor, Atlanta, Boston, Los Angeles, New Haven, New Hyde Park, New York, Palo Alto, Philadelphia, Rochester, Salt Lake City, and San Francisco, United StatesSee the 14 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 32,000 people, planned
- Started
- 15 Nov 2010
- Expected to end
- Dec 2032
- Type of study
- Observational
- Record updated
- 30 January 2026
Who can take part
- Age
- Up to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Signed consent form
Who cannot take part
- Isolated patent foramen ovale
- Isolated prematurity-associated patent ductus arteriosus
Where in United States
Also in 1 other country, 1 site
- University of Michigan HealthAnn Arbor, United States
- Children's Healthcare of AtlantaAtlanta, United States
- Brigham & Women's HospitalBoston, United States
- Children's Hospital, BostonBoston, United States
- Children's Hospital Los AngelesLos Angeles, United States
- Yale UniversityNew Haven, United States
- Cohen Children's Medical Center New YorkNew Hyde Park, United States
- Columbia University Medical CenterNew York, United States
- Mount Sinai School of MedicineNew York, United States
- Stanford UniversityPalo Alto, United States
- Children's Hospital PhiladelphiaPhiladelphia, United States
- University of RochesterRochester, United States
- University of UtahSalt Lake City, United States
- University of California San FranciscoSan Francisco, United States
About the trial
What the trial wants to find out
Congenital heart defects (CHD) are the most common major human birth malformation, affecting ~8 per 1,000 live births. CHD are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. Current understanding of the etiology of pediatric cardiovascular disorders is limited.
Read full original descriptionShow less
The Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is a multi-center, prospective observational cohort study. Participants will be recruited from the Pediatric Cardiac Genomics Consortium's (PCGC) centers of the NHLBI-sponsored Bench to Bassinet (B2B) Program. Biological specimens will be obtained for genetic analyses, and phenotype data will be collected by interview and from medical records. State-of-the-art genomic technologies will be used to identify common genetic causes of CHD and genetic modifiers of clinical outcome.
To accomplish this, the PCGC will develop and maintain a biorepository of specimens (DNA) and genetic data, along with detailed, phenotypic and clinical outcomes data in order to investigate relationships between genetic factors and phenotypic and clinical outcomes in congenital heart disease.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Increased endothelial sclerostin caused by elevated DSCAM mediates multiple trisomy 21 phenotypes.The Journal of clinical investigation, 2024
- Contribution of Previously Unrecognized RNA Splice-Altering Variants to Congenital Heart Disease.Circulation. Genomic and precision medicine, 2023
- Genome-Wide De Novo Variants in Congenital Heart Disease Are Not Associated With Maternal Diabetes or Obesity.Circulation. Genomic and precision medicine, 2022
- Genome-Wide Association Studies of Conotruncal Heart Defects with Normally Related Great Vessels in the United States.Genes, 2021
- Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy.The Journal of clinical investigation, 2021
- De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease.Circulation. Genomic and precision medicine, 2020
- Record updated
- 30 January 2026